Abstract 622P
Background
CCL26 is widely found in various tissues of the human body and mainly acts on eosinophils. However, its role in tumors remains unclear. In this study, we aimed to investigate the role of CCL26 in pan-cancer.
Methods
Data were downloaded from University of California Santa Cruz (UCSC) Xena and The Cancer Genome Atlas (TCGA). The expression of CCL26 was investigated in TCGA_GTEx, TCGA and TCGA paired samples, respectively. Subsequently, Kaplan-Meier analyses were performed on 33 TCGA tumors, and clinical correlation and one-way Cox regression analyses were performed on tumors in which CCL26 affected prognosis. In addition, we selected more than 500 representative tumors of renal clear cell carcinoma (KIRC) to construct a nomogram model to confirm the prognostic value of CCL26 in the tumors. In addition, CCL26 there was an association with immune cell infiltration. Mechanistically, we performed functional enrichment analysis to explore potential signaling pathways in which CCL26 may be involved.
Results
Our study found that CCL26 expression was significantly up-regulated in 20 tumors and down-regulated in 6. High expression of CCL26 was associated with shorter overall survival (OS) in adrenocortical carcinoma (ACC), bladder uroepithelial carcinoma (BLCA), renal clear cell carcinoma (KIRC), papillary renal cell carcinoma (KIRP), and mesothelioma (MESO). CCL26 had high predictive accuracy (AUC > 0.9) for five cancers, including cholangiocarcinoma (CHOL; AUC = 0.952, CI: 0.890-0=1.000), renal smoky cell carcinoma (KICH; AUC = 0.928, CI: 0.875- 0.981), lung squamous cell carcinoma (LUSC; AUC = 0.928, CI: 0.905-0.951), skin melanoma (SKCM; AUC = 0.936, CI: NA-NA), thymoma (THYM; AUC = 0.933, CI: 0.829-1.000). -1.000).
Conclusions
CCL26 may serve as a potential prognostic biomarker and a promising target for cancer immunotherapy. It is also associated with clinical outcomes and immune microenvironment in a variety of tumors, and may influence tumor development by regulating signaling pathways of stem cell pluripotency and immune-related pathways.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
123P - Spatial molecular profiling identifies FGF20 upregulation on cancer-associated fibroblast and FGFR2-PI3K/Akt activation in tumor cells of sporadic early-onset colon cancer
Presenter: Dave Hoon
Session: Poster Display
Resources:
Abstract
124P - Characteristics, prognosis and therapeutic effects of non-V600 BRAF mutated colorectal cancer
Presenter: Lalida Arsa
Session: Poster Display
Resources:
Abstract
125P - Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice
Presenter: Alexey Tryakin
Session: Poster Display
Resources:
Abstract
126P - From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neadjuvant therapy (TNT): A retrospective analysis
Presenter: Valeria Pusceddu
Session: Poster Display
Resources:
Abstract
127P - A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness
Presenter: Takayuki Yoshino
Session: Poster Display
Resources:
Abstract
128TiP - A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
140P - Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Presenter: Hoo Hwoei Fen Soo
Session: Poster Display
Resources:
Abstract
141P - Early phase trials outcomes in refractory upper GI cancers: A 10-year analysis from the SCRI UK phase I unit
Presenter: Antonella Cammarota
Session: Poster Display
Resources:
Abstract
142P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract